Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients

被引：0
|
作者：
Sara E. Mole
Angela Schulz
Eben Badoe
Samuel F. Berkovic
Emily C. de Los Reyes
Simon Dulz
Paul Gissen
Norberto Guelbert
Charles M. Lourenco
Heather L. Mason
Jonathan W. Mink
Noreen Murphy
Miriam Nickel
Joffre E. Olaya
Maurizio Scarpa
Ingrid E. Scheffer
Alessandro Simonati
Nicola Specchio
Ina Von Löbbecke
Raymond Y. Wang
Ruth E. Williams
机构：
[1] University College London,Korle Bu Teaching Hospital
[2] Universitätsklinikum Hamburg-Eppendorf,Austin Health Victoria
[3] University of Ghana Medical School,Golisano Childrens’ Hospital
[4] University of Melbourne,Regional Coordinating Center for Rare Diseases
[5] Nationwide Children’s Hospital,Department of Surgery, Dentistry, Paediatrics and Gynaecology
[6] Hospital de Niños de La Santísima Trinidad,undefined
[7] Universidade de São Paulo Faculdade de Medicina de Ribeirão Preto,undefined
[8] Coufetery Comms,undefined
[9] University of Rochester Medical Center,undefined
[10] Batten Disease Support and Research Association (BDSRA),undefined
[11] Children’s Hospital of Orange County,undefined
[12] University Hospital Udine,undefined
[13] University of Verona School of Medicine,undefined
[14] Ospedale Pediatrico Bambino Gesù,undefined
[15] Practice for Child Physiotherapy,undefined
[16] Evelina,undefined
[17] London Children’s Hospital,undefined
[18] NIHR Great Ormond Street Hospital Biomedical Research Centre,undefined
[19] Royal Children’s Hospital,undefined
[20] Florey and Murdoch Children’s Research Institutes,undefined
来源：
Orphanet Journal of Rare Diseases | / 16卷
关键词：
Expert mapping; Guideline development program; CLN2; Batten; Neurodegenerative disorder; Key Opinion Leader; Modified-Delphi;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Clinical utility of a sponsored gene panel testing program for pediatric epilepsy and CLN2 disease diagnosis: Results from 4246 tests
    Pang, Tiffany
    Leal-Pardinas, Fernanda
    Truty, Rebecca
    McKnight, Dianalee A.
    Johnson, Britt
    Morales, Ana
    Bristow, Sara L.
    Izzo, Emanuela
    Cohen-Pfeffer, Jessica
    Sankar, Raman
    Koh, Sookyong
    Wirrell, Elaine C.
    Millichap, John J.
    Aradhya, Swaroop
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S82 - S82
  • [32] An integrated strategy for the diagnosis of neuronal ceroid lipofuscinosis types 1 (CLN1) and 2 (CLN2) in eleven Latin American patients
    Kohan, R.
    Cismondi, I. A.
    Dodelson Kremer, R.
    Muller, V. J.
    Guelbert, N.
    Tapia Anzolini, V.
    Fietz, M. J.
    Oller Ramirez, A. M.
    Noher Halac, I.
    CLINICAL GENETICS, 2009, 76 (04) : 372 - 382
  • [33] Development of the "Hamburg best practice guidelines for ICV-enzyme replacement therapy (ERT) in CLN2 disease" based on 5 years treatment experience in 48 patients
    Schwering, Christoph
    Wibbeler, Eva
    Miriam, Nickel
    Schulz, Angela
    MOLECULAR GENETICS AND METABOLISM, 2020, 129 (02) : S146 - S146
  • [34] OCT Biomarkers in Ocular CLN2 Disease in Patients Treated With Intraventricular Enzyme Replacement Therapy
    Huang, Wei Chieh
    Ohnsman, Christina M.
    Atiskova, Yevgeniya
    Falabella, Paulo
    Spitzer, Martin S.
    Schulz, Angela
    Dulz, Simon
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (08)
  • [35] CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis)
    Kohlschuetter, Alfried
    Schulz, Angela
    PEDIATRIC ENDOCRINOLOGY REVIEWS PER, 2016, 13 : 682 - 688
  • [36] Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration
    Kim, Aryun
    Grover, Anita
    Hammon, Kevin
    de Hart, Greg
    Slasor, Peter
    Cherukuri, Anu
    Ajayi, Temitayo
    Jacoby, David
    Schulz, Angela
    Specchio, Nicola
    de Los Reyes, Emily
    Gissen, Paul
    Henshaw, Joshua W.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (02): : 635 - 644
  • [37] Loss of visual function associated with photoreceptor degeneration in CLN2 disease
    Ohnsman, Christina
    Huang, Wei Chieh
    Atiskova, Yevgeniya
    Wildner, Jan
    Falabella, Paulo
    Schulz, Angela
    Dulz, Simon
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 95 - 95
  • [38] Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy
    Specchio, Nicola
    Pietrafusa, Nicola
    Trivisano, Marina
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2020, 16 : 213 - 222
  • [39] Speech, Language and Non-verbal Communication in CLN2 and CLN3 Batten Disease
    Morison, Lottie D.
    Whiteman, Ineka T.
    Vogel, Adam P.
    Tilbrook, Lisa
    Fahey, Michael C.
    Braden, Ruth
    Bredebusch, Joanna
    Hildebrand, Michael S.
    Scheffer, Ingrid E.
    Morgan, Angela T.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2025, 48 (01)
  • [40] The relationship between the expanded neuronal ceroid lipofuscinosis 2 (CLN2) clinical rating scale for motor function (CLN2 CRS-MX) and GAITRite® parameters
    Hagenah, Luca
    Schwering, Christoph
    Wilson, Catherine
    Wibbeler, Eva
    Westermann, Lena Marie
    Cho, Yoonjin
    Nickel, Miriam
    Schulz, Angela
    Phillips, Dawn
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 55 - 56
12345